Remdesivir Market Outlook 2030
Remdesivir is a broad spectrum anti-viral medication which was firstly developed by Gilead Sciences. It is administered through injection into the vein. Remdesivir is a prodrug of nucleotide. In COVID-19 pandemic remdesivir was authorized for emergency treatment of COVID-19 around the 50 countries as per the recommendation of WHO in November 2020. Originally remdesiver is used in treatment of hepatitis C, Ebola virus, and Marburg virus infections. Moreover, remdesivir can be used in treatment of respiratory infections, feline infections, and arenaviruses. Nausea, liver infection, low blood pressure, and vomiting are common adverse effects of remdesivir.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the remdesivir market.
Top Impacting Factors
- Rise in cases of viral infections, surge in unhygienic practices in rural areas, increase in demand to overcome from viral infections, surge in cases of COVID-19 across the globe, increase in geriatric population, and rise in hospital acquired infections are the key factors that drive the growth of the remdesivir market.
- In addition, rise in investment in health care sector, occurrence of various pandemic diseases such as Ebola and COVID-19, government initiatives to promote manufacturing of remdesivir, emerging modern healthcare technologies in developing countries, R & D activities to improve quality of remdesivir, launch of novel drugs, and joint ventures, collaboration, and agreements between key market players can boost the growth of the remdesivir market.
- However, shortage of remdesivir supply and availability of substitutes can hinder the growth of the market.
- Contrarily, favourable reimbursement policies by governments and fast track regulatory approvals are expected to offer lucrative opportunities for the expansion of the market.
Market Trends
New Product Launches to Flourish the Market
In 2020, Jubilant Life Sciences announced launch of remdesivir for injection 100mg vial under the brand name JUBI-R. This injection can be used in treatment of COVID-19.
In 2020, Mylan announced commercial launch of remedesivir for injection under the brand name DESREMTM in India. This is a licensed drug for treatment of COVID-19 patients.
In 2020, Zydus Cadila announced launch of remdesivir lyophilised injection 100mg/vial. This injection can be used for patients suffering from SARS-CoV2.
Key Benefits of the Report
- This study presents the analytical depiction of remdesivir market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the remdesivir market share.
- The current market is quantitatively analyzed to highlight the remdesivir market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Remdesivir Market Report
- Which are the leading players active in the remdesivir market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "remdesivir"?
- What is "remdesivir" market prediction in the future?
- Who are the leading global players in the "remdesivir" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "remdesivir" market report?
Remdesivir Market, by Dosage Report Highlights
| Aspects | Details |
 By Dosage |
|
 By Form |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt. Ltd.), Eva Pharma Pvt. Ltd., Hetero Labs Pvt. Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceuticals Industries Ltd., Jubilant Life Sciences Ltd., Pfizer Ltd., Gilead Sciences India Private Limited, Zydus Cadila Healthcare Ltd. |
Loading Table Of Content...
